Published Jul 30, 2026, 9:10 AM ET · Updated 3 months ago · 1 source
J&J granted FDA priority review for Rybrevant Faspro in head and neck cancer
Seeking Alpha
·
Original Report
J&J granted FDA priority review for Rybrevant Faspro in head and neck cancer